Nektar Therapeutics
NASDAQ:NKTRBiotechnology
Healthcare
$32.54 -2.04%
-$1.24 today
- Market cap
- $933.51M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
52W Low $8.27High $109.00
Volume 0.86M
Average 1.00M
Balance Sheet
Inspect the capital base behind the business.
Assets
$280.41M
FY 2025 · Annual
-7.7% YoYLiabilities
$190.57M
FY 2025 · Annual
-21.6% YoYEquity
$89.83M
FY 2025 · Annual
+47.9% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.22M | 88.23M | 35.28M | 44.25M | 15.12M |
| Short-term Investments | 708.74M | 416.75M | 268.34M | 210.97M | 230.64M |
| Net Receivables | 22.49M | 8.4M | 2.25M | 1.61M | 1.78M |
| Inventory | 15.8M | 19.2M | 16.1M | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 795.58M | 545.97M | 330.7M | 261.29M | 266.27M |
| Property, Plant & Equipment (Net) | 177.54M | 85.89M | 36.86M | 11.82M | 5M |
| Goodwill | 76.5M | 76.5M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 64.83M | 0 | 25.83M | 26.09M | 3.49M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.74M | 2.25M | 4.64M | 4.65M | 5.65M |
| Total Non-current Assets | 321.61M | 164.63M | 67.33M | 42.56M | 14.14M |
| Total Assets | 1.12B | 710.6M | 398.03M | 303.85M | 280.41M |
| Account Payables | 9.75M | 12.98M | 9.85M | 11.56M | 10.77M |
| Short-term Debt | 0 | 0 | 0 | 0 | 20.5M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15.74M | 9.58M | 5.55M | 5.55M | 22.27M |
| Total Current Liabilities | 85.2M | 68.2M | 51.27M | 61.4M | 53.54M |
| Long-term Debt | 0 | 0 | 0 | 0 | 63.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 226.75M | 162.93M | 117.26M | 99.02M | 8.63M |
| Total Non-current Liabilities | 352.48M | 275.76M | 215.78M | 181.71M | 137.04M |
| Total Liabilities | 437.68M | 343.96M | 267.05M | 243.11M | 190.57M |
| Common Stock | 19K | 19K | 19K | 19K | 2K |
| Retained Earnings | (2.83B) | (3.2B) | (3.48B) | (3.6B) | (3.76B) |
| Accumulated OCI | (4.16M) | (6.91M) | 80K | 61K | 17K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 679.51M | 366.64M | 130.99M | 60.74M | 89.83M |
| Total Debt | 143.18M | 131.5M | 117.78M | 102.56M | 148.91M |
| Net Debt | 117.96M | 43.27M | 82.5M | 58.31M | 133.79M |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $39.1M |
| Short-term Investments | $645.2M |
| Receivables | $4.8M |
| Other Current | $50.3M |
| Total Current Assets | $739.4M |
| PP&E (Net) | $4.3M |
| Long-term Investments | $340.5M |
| Other Non-current | $11.0M |
| Total Non-current Assets | $355.7M |
| Total Assets | $1.1B |
Analysis
Selected assets total $1.1B for Latest. The largest visible component is Short-term Investments at $645.2M, about 58.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| S-8 | S-8 filing | Oct 20, 2026 |
How much cash does NKTR have?
Nektar Therapeutics (NKTR) reported $15.12M in cash and equivalents in fiscal 2025.
How much debt does NKTR carry?
Nektar Therapeutics (NKTR) reported $148.91M of total debt, with net debt of $133.79M.
Continue the stock analysis
Jump to another research area for this company.